40th Czech and Slovak Endoscopic Days, 19th Endoscopic Day IKEM
Congress reportGastroent Hepatol 2018; 72(3): 265.
pdf Martin Vašátko, Radka VaníčkováVedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical practice
Original articleGastroent Hepatol 2019; 73(1): 25–31. doi:10.14735/amgh201925
SummaryLiteraturepdf Martin Kolář, Dana Ďuricová, Martin Bortlík, Karolína Pudilová, Veronika Hrubá, Naděžda Machková, Katarína Mitrová, Karin Malíčková, Martin Lukáš, Martin Vašátko, Radka Vaníčková, Milan LukášEarly vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel disease
Original articleGastroent Hepatol 2019; 73(1): 32–36. doi:10.14735/amgh201932
SummaryLiteraturepdf Karolína Pudilová, Martin Kolář, Dana Ďuricová, Karin Malíčková, Veronika Hrubá, Naděžda Machková, Radka Vaníčková, Katarína Mitrová, Martin Lukáš, Martin Vašátko, Milan Lukáš, Martin Bortlík